par Schulman, Claude ;Boccon-Gibod, Laurent
Référence European urology. Supplement, 5, 3 SPEC. ISS., page (395-396)
Publication Publié, 2006-04
Article révisé par les pairs
Résumé : Large variations in practice are seen in applying hormonal therapy for prostate cancer. In contrast to older luteinizing hormone releasing hormone formulations, Eligard seems to achieve and maintain testosterone levels similar to those obtained by surgical castration. Oncologic and functional outcomes are more dependent on the surgeon than on the choice of the surgical procedure. © 2006 Elsevier B.V. All rights reserved.

Documents en relation

DI-fusion